Navigation Links
Celsion Completes Enrollment in Phase I Liver Cancer Study

dy of patients with recurrent breast cancer on the chest wall under the care of Dr. Kim Blackwell, the principal investigator.

About Celsion: Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System.

Celsion has also developed a microwave based system, the Prolieve Thermodilatation(R) system, for the treatment of benign prostatic hyperplasia which is marketed in the United States under an exclusive distribution agreement with Boston Scientific Corporation. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

NO ENDORSEMENT OF CELSION CORPORATION OR ANY OF ITS PRODUCTS OR SERVICES BY THE NATIONAL INSTITUTES OF HEALTH OR THE CLINICAL CENTER IS INTENDED OR SHOULD BE INFERRED.

Contact

Celsion Corporation
Tony Deasey, 410-290-5390
tony@celsion.com
or
General
'"/>




Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Celsion Completes Enrollment Phase Liver Cancer Study
(Date:11/25/2008)...e recovery , , Audio and Web Video Resource...o Clinic News Blog. Please see the bottom of this ...nn., Nov. 25 A Mayo Cli...t think they,re having a stroke -- and as a result...worsens. The findings appear in the current issue ...
(Date:11/25/2008)... Nov. 25 Proteolix, Inc., a,leade...eutics that target,protein degradation pathways i... that data from two ongoing Phase 2 clinical trial...ented at the upcoming 50th Annual Meeting of the,... is the first in a new class,of specific proteaso...
(Date:11/25/2008)...nical Trial to Assess Survival of Patients Receivi...sectable Hepatocellular Carcinoma , , BELLE... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
(Date:11/24/2008)...RNewswire/ -- Domino,s Pizza (NYSE: DPZ ), the,...ing up to raise dough for,the kids of St. Jude Ch...,Thanks and Giving campaign. Domino,s customers w...int of purchase to benefit the children of St. Jud...hone or when ordering online at, www.dominos.com ...
Breaking Medicine Technology:Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 1July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 2July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 4Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 1Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 2Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 1Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 2Two New Jersey Hormone Therapy Lawsuits Dismissed 6534 1
...O VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AV... the presentation of,Phase III data, including eff... outcomes in patients with diabetic peripheral,neu...al drug,Zenvia(TM) (dextromethorphan/quinidine (DM...ist. The data were accepted as,late-breakers, and...
...RIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Arche...overing and developing,aptamers, announced the suc... aptamer therapeutic, ARC1779. ARC1779 is designed... aggregation of,platelets by inhibiting the bindin...tor on platelets. Activated vWF is scientifically,...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3
(Date:12/2/2008)...Resilient, Cost and Energy Efficient Information I... EMC Corporation (NYSE: EMC ), th...ions, today announced that the Daughters of Charit...ospitals spanning the California coast, has consol...s continuity functions to deliver new online clini...
(Date:12/2/2008)...valuate Efficacy of Commercially Available Hypomet...Dec. 2 Eisai Corporation of North ...the first clinical trial evaluating the activity o...o Vidaza(R) (azacitidine) in adult patients with i...splastic syndromes (MDS), a potentially life-threa...
(Date:12/2/2008)...arotz Dental is now one of only two dental,practi...ew Attachment,Procedure). This is the only laser...approved for new attachment of gum and bone tissue...sue, without removing healthy tissue, maintains,t...in and discomfort to the,patient, closes the peri...
(Date:12/2/2008)...Call/ -- Global Med Technologies(R), Inc.,("Globa...), an international,e-Health, medical information...opean subsidiary, Inlog S.A., has licensed its Edg...rveur" in France, to 21 Assistance Publique -,Hop...3,000 patient beds. For,Global Med, this project ...
Breaking Medicine News(10 mins):Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Small, comes in a compact carrying case, carrying pouch included.
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure.
Medicine Products: